Gerds AT et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. ASH 2019;Abstract 557.

Harrison CN et al. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (mf) therapy and after prior ruxolitinib (rux): Results from the JAKARTA and JAKARTA2 trials. EHA 2021;Abstract S203.

Harrison CN et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019;Abstract 7057.

Harrison CN et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4(7):e317-24. Abstract

Kiladjian J-J et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 2020;7(3):e226-37. Abstract

Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol. 2015;1(5):643-51. Abstract

Tremblay D et al. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Advances 2020;4(23):5929-35. Abstract

Vannucchi AM et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372(5):426-35. Abstract

Verstovsek S et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy 2014;7:13-21. Abstract